Business Description
Checkpoint Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1628282063
Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -2.78 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -107.1 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -70.3 | |||||
3-Year EBITDA Growth Rate | 12.5 | |||||
3-Year EPS without NRI Growth Rate | 8.1 | |||||
3-Year FCF Growth Rate | 5 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.17 | |||||
9-Day RSI | 45.7 | |||||
14-Day RSI | 46.93 | |||||
6-1 Month Momentum % | 33.79 | |||||
12-1 Month Momentum % | 12.28 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.26 | |||||
Quick Ratio | 0.26 | |||||
Cash Ratio | 0.23 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -58.7 | |||||
Shareholder Yield % | -23.23 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -45501.28 | |||||
Net Margin % | -54444.87 | |||||
FCF Margin % | -43616.44 | |||||
ROA % | -632.34 | |||||
ROIC % | -1697.48 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 765 | |||||
EV-to-EBIT | -2.77 | |||||
EV-to-Forward-EBIT | -3.08 | |||||
EV-to-EBITDA | -2.77 | |||||
EV-to-Forward-EBITDA | -3.08 | |||||
EV-to-Revenue | 1261.09 | |||||
EV-to-Forward-Revenue | 543.53 | |||||
EV-to-FCF | -2.87 | |||||
Earnings Yield (Greenblatt) % | -36.1 | |||||
FCF Yield % | -33.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Checkpoint Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.073 | ||
EPS (TTM) (€) | -1.752 | ||
Beta | 1.18 | ||
Volatility % | 74.81 | ||
14-Day RSI | 46.93 | ||
14-Day ATR (€) | 0.074642 | ||
20-Day SMA (€) | 2.0793 | ||
12-1 Month Momentum % | 12.28 | ||
52-Week Range (€) | 1.286 - 3.038 | ||
Shares Outstanding (Mil) | 45.02 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Checkpoint Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Checkpoint Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Checkpoint Therapeutics Inc Frequently Asked Questions
What is Checkpoint Therapeutics Inc(FRA:CZTA)'s stock price today?
The current price of FRA:CZTA is €2.00. The 52 week high of FRA:CZTA is €3.04 and 52 week low is €1.29.
When is next earnings date of Checkpoint Therapeutics Inc(FRA:CZTA)?
The next earnings date of Checkpoint Therapeutics Inc(FRA:CZTA) is 2024-11-13 Est..
Does Checkpoint Therapeutics Inc(FRA:CZTA) pay dividends? If so, how much?
Checkpoint Therapeutics Inc(FRA:CZTA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |